Sagimet Biosciences SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 22, 2026, 7:15 a.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedSagimet Biosciences Updates Investor Presentation; First AURORA Phase 3 Patient Dosed, Cash Cited at $257.6 Million
8-KSept. 30, 2026, 6 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Financial statements and exhibits
8-KSept. 30, 2026, 6:09 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
8-KAug. 13, 2026, 7:05 a.m. ETView on SEC.gov
Other events
8-KAug. 11, 2026, 7:35 a.m. ETView on SEC.gov
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits